Business Context and Reporting Period
This Form 8-K Current Report was filed by Baxter International Inc. on October 28, 2015. The filing addresses significant changes in corporate leadership, specifically the departure of the current Chief Executive Officer and the appointment of a successor.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and personnel changes.
Material Changes
- Departure of CEO: Robert L. Parkinson, Jr. announced his retirement as Chief Executive Officer, President, and Chairman of the Board, effective December 31, 2015.
- Appointment of CEO: José E. Almeida was appointed to serve as Chief Executive Officer and President, effective January 1, 2016.
- Board Election: Mr. Almeida was appointed to the 2017 class of the Board and elected as Chairman of the Board, effective January 1, 2016.
Management Commentary and Compensation Details
Mr. Almeida brings over 20 years of experience in the medical products industry, including prior leadership roles at Covidien plc and the Carlyle Group. His compensation package, effective upon appointment, includes:
- Base Salary: $1,300,000 annually.
- Target Bonus: 135% of annual base salary under the Management Incentive Compensation Program.
- Long-Term Equity Incentives: An initial grant valued at $9,000,000, consisting of 720,000 stock options and 126,086 performance share units (split between total shareholder return and return on capital measures).
- Severance: Eligible for two years of base salary and target bonus in the event of involuntary termination without cause or termination with good reason within five years.
Investor Verification Checklist
- Verify the exact effective dates for the transition of CEO and Chairman roles (December 31, 2015, and January 1, 2016).
- Review the attached Offer Letter (Exhibit 10.1) and Equity Plan (Exhibit 10.2) for specific vesting schedules and performance metrics.
- Confirm the terms of the change of control agreement referenced in the severance package.
- Check subsequent filings for any updates to the transition timeline or additional executive appointments.